Unlocking the Potential of PAX6-AS1: A Drug Target and Biomarker

Target Name: PAX6-AS1

NCBI ID: G440034

PAX6-AS1

Other Name(s): DKFZp686K1684 | FLJ55835 | PAX6 antisense RNA 1

Unlocking the Potential of PAX6-AS1: A Drug Target and Biomarker

Introduction

PAX6-AS1, also known as DKFZp686K1684, is a protein that is expressed in various tissues and cell types in the human body. Its function and structure have been extensively studied, and its potential as a drug target and biomarker have gained significant attention in recent years. In this article, we will explore the biology and potential implications of PAX6-AS1 in drug development and disease diagnosis.

Structure and Function

PAX6-AS1 is a 21-kDa transmembrane protein that is characterized by its extracellular domain, which is composed of a unique farnesylated cysteine 鈥嬧?媟epeat (CSN-CSN-CSN) and a 24 amino acid tail. The protein is expressed in various tissues, including the brain, heart, liver, and pancreas, and has been shown to play a role in various physiological processes, including cell signaling, inflammation, and stress resistance.

One of the most significant features of PAX6-AS1 is its ability to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This interaction is mediated by its unique farnesylated cysteine 鈥嬧?媟epeats, which allows the protein to form a covalent complex with the protein kinase PDK4. This interaction between PAX6-AS1 and PDK4 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and stress response.

In addition to its role in signaling pathways, PAX6-AS1 has also been shown to act as a biomarker for various diseases. For example, it has been used as a biomarker for cancer, including breast, lung, and ovarian cancers. Studies have shown that higher levels of PAX6-AS1 expression are associated with poor prognosis in patients with these cancers. Additionally, PAX6-AS1 has also been shown to be involved in the development of cardiovascular disease, including myocardial infarction and hypertension.

Drug Target Potential

The potential drug targets for PAX6-AS1 are vast and varied. Its interaction with PDK4 makes it a potential target for inhibitors of PDK4, which are currently being developed as anti-cancer drugs. Additionally, the protein's role in cell signaling and stress response make it a potential target for drugs that target stress response pathways. Furthermore, its role in the development of cardiovascular disease makes it a potential target for drugs that target the cardiovascular system.

In conclusion, PAX6-AS1 is a protein with significant potential as a drug target and biomarker. Its unique farnesylated cysteine 鈥嬧?媟epeats and its ability to interact with various signaling pathways make it a promising target for inhibitors of PDK4 and other drugs. Further research is needed to fully understand the biology and potential implications of PAX6-AS1, and to develop safe and effective drugs that target this protein.

Protein Name: PAX6 Antisense RNA 1

The "PAX6-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAX6-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets